Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Trifluoroacetate | HCID 84468 | — |
| Reactant | HCID 178464306 | HCID 178464306 | — |
| Product | HCID 178464317 | HCID 178464317 | 63.1% |
Reaction Steps
In the same manner as for step V1 of example 15 (see below), 100 mg of 1-{2-[4-(3,3-diethylureido)-1-(tetrahydropyran-2-yl)-1H-pyrazol-3-yl]-6-fluoro-3H-benzimidazol-5-yl}-1-(2-dimethylaminoethyl)-3,3-diethylurea (stage 5, example 15) are deprotected, and 54 mg of 1-{2-[4-(3,3-diethylureido)-1H-pyrazol-3-yl]-6-fluoro-3H-benzimidazol-5-yl}-1-(2-dimethylaminoethyl)-3,3-diethylurea are isolated in the form of a trifluoroacetate salt. 1H NMR (300 MHz, DMSO-d6, δ in ppm), for this batch, we observe a 60%-40% resolution of tautomers with: 0.75 (m, 6H); 1.22 (m, 6H); from 2.30 to 2.86 (broad m partially masked, 8H); 3.02 (q, J=7.0 Hz, 4H); 3.42 (q, J=7.0 Hz, 4H); 3.64 (broad m, 2H); 7.36 (m, 1H); 7.52 (m, 1H); 8.02 (s, 1H); 9.35 (broad m, 1H); 9.71 (s, 0.4H); 9.74 (s, 0.6H); 13.1 (broad s, 1H); 13.15 (broad s, 0.4H); 13.2 (broad s, 0.6H). ES mass spectrum: 502(+)=(M+H)(+)
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US09126969B2 |
|---|
| Source dataset | uspto-grants-2015_09 |
|---|
| ORD ID | ord-65e3d020698a4b079accd4ba4c78ba24 |
|---|
| Source note | uspto-grants-2015_09 |
|---|